nach oben

Der Nervenarzt

Erschienen in:

07.07.2016 | Parkinson-Krankheit | Leitthema

Zellersatz und adulte Neurogenese beim idiopathischen Parkinson-Syndrom

verfasst von: F. Marxreiter, A. Storch, Prof. Dr. J. Winkler

Erschienen in: Der Nervenarzt | Ausgabe 8/2016

Einloggen, um Zugang zu erhalten

Zusammenfassung

Progrediente neurodegenerative Prozesse führen zu einem Neuronenverlust beim idiopathischen Parkinson-Syndrom (IPS), der häufigsten altersassoziierten Bewegungsstörung. Die für die motorische Symptomatik des IPS verantwortliche Degeneration dopaminerger Neurone der Substantia nigra macht den Ersatz dieser Nervenzellen durch Transplantation sehr attraktiv. Aktuelle Entwicklungen der Stammzelltechnologie ermöglichen eine Optimierung des Transplantats und können zu einer Reaktivierung dieser Therapiestrategie führen. Zusätzlich gehen die neurodegenerativen Prozesse des IPS mit einer gestörten adulten Nervenzellneubildung (Neurogenese) und damit einer Beeinträchtigung der hirneigenen zellulären Plastizität einher. Nichtmotorische Symptome können daher nicht ausschließlich durch neurodegenerative Prozesse, sondern auch im Rahmen einer gestörten adulten Neurogenese erklärbar sein. Die Kombination aus Neurodegeneration und konsekutiv gestörter adulter Neurogenese könnte so beim IPS zu einer erhöhten Vulnerabilität des limbischen und des olfaktorischen Systems führen.

Baker SA, Baker KA, Hagg T (2004) Dopaminergic nigrostriatal projections regulate neural precursor proliferation in the adult mouse subventricular zone. Eur J Neurosci 20:575–579. doi:10.1111/j.1460-9568.2004.03486.xCrossRefPubMed

Barone P, Antonini A, Colosimo C et al (2009) The PRIAMO study: A multicenter assessment of nonmotor symptoms and their impact on quality of life in Parkinson’s disease. Mov Disord 24:1641–1649. doi:10.1002/mds.22643CrossRefPubMed

Bartels T, Choi JG, Selkoe DJ (2011) α‑Synuclein occurs physiologically as a helically folded tetramer that resists aggregation. Nature 477:107–110. doi:10.1038/nature10324CrossRefPubMedPubMedCentral

Biebl M, Cooper CM, Winkler J, Kuhn HG (2000) Analysis of neurogenesis and programmed cell death reveals a self-renewing capacity in the adult rat brain. Neurosci Lett 291:17–20CrossRefPubMed

Blum R, Lesch K‑P (2015) Parkinson’s disease, anxious depression and serotonin-zooming in on hippocampal neurogenesis. J Neurochem 135:441–444. doi:10.1111/jnc.13278CrossRefPubMed

Braak E, Braak H (1999) Silver staining method for demonstrating Lewy bodies in Parkinson’s disease and argyrophilic oligodendrocytes in multiple system atrophy. J Neurosci Methods 87:111–115CrossRefPubMed

Braak H, Del Tredici K, Rüb U et al (2003) Staging of brain pathology related to sporadic Parkinson’s disease. Neurobiol Aging 24:197–211CrossRefPubMed

Braak H, Rüb U, Del Tredici K (2006) Cognitive decline correlates with neuropathological stage in Parkinson’s disease. J Neurol Sci 248:255–258. doi:10.1016/j.jns.2006.05.011CrossRefPubMed

Braak H, Rüb U, Gai WP, Del Tredici K (2003) Idiopathic Parkinson’s disease: possible routes by which vulnerable neuronal types may be subject to neuroinvasion by an unknown pathogen. J Neural Transm (Vienna) 110(5):517–536. doi:10.1007/s00702-002-0808-2

10.

Curtis MA (2007) Human neuroblasts migrate to the olfactory bulb via a lateral ventricular extension. Science 315:1243–1249. doi:10.1126/science.1136281CrossRefPubMed

11.

Danzer KM, Haasen D, Karow AR et al (2007) Different species of alpha-synuclein oligomers induce calcium influx and seeding. J Neurosci 27:9220–9232. doi:10.1523/JNEUROSCI.2617-07.2007CrossRefPubMed

12.

Deng W, Aimone JB, Gage FH (2010) New neurons and new memories: how does adult hippocampal neurogenesis affect learning and memory? Nat Rev Neurosci 11:339–350. doi:10.1038/nrn2822CrossRefPubMedPubMedCentral

13.

Desplats P, Lee H‑J, Bae E‑J et al (2009) Inclusion formation and neuronal cell death through neuron-to-neuron transmission of alpha-synuclein. Proc Natl Acad Sci U S A 106:13010–13015. doi:10.1073/pnas.0903691106CrossRefPubMedPubMedCentral

14.

Deusser J, Schmidt S, Ettle B et al (2015) Serotonergic dysfunction in the A53 T alpha-synuclein mouse model of Parkinson’s disease. J Neurochem 135:589–597. doi:10.1111/jnc.13253CrossRefPubMedPubMedCentral

15.

Doetsch F, García-Verdugo JM, Alvarez-Buylla A (1997) Cellular composition and three-dimensional organization of the subventricular germinal zone in the adult mammalian brain. J Neurosci 17:5046–5061PubMed

16.

Eriksson PS, Perfilieva E, Björk-Eriksson T et al (1998) Neurogenesis in the adult human hippocampus. Nat Med 4:1313–1317. doi:10.1038/3305CrossRefPubMed

17.

Ernst A, Frisén J (2015) Adult neurogenesis in humans- common and unique traits in mammals. PLoS Biol 13:e1002045. doi:10.1371/journal.pbio.1002045CrossRefPubMedPubMedCentral

18.

Freed CR, Greene PE, Breeze RE et al (2001) Transplantation of embryonic dopamine neurons for severe Parkinson’s disease. N Engl J Med 344:710–719. doi:10.1056/NEJM200103083441002CrossRefPubMed

19.

Freudenberg U, Hermann A, Welzel PB et al (2009) A star-PEG–heparin hydrogel platform to aid cell replacement therapies for neurodegenerative diseases. Biomaterials 30:5049–5060. doi:10.1016/j.biomaterials.2009.06.002CrossRefPubMed

20.

Freundlieb N, François C, Tandé D et al (2006) Dopaminergic substantia nigra neurons project topographically organized to the subventricular zone and stimulate precursor cell proliferation in aged primates. J Neurosci 26:2321–2325. doi:10.1523/JNEUROSCI.4859-05.2006CrossRefPubMed

21.

Gibb WR, Lees AJ (1988) The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson’s disease. J Neurol Neurosurg Psychiatr 51(6):745–752. doi:10.1136/jnnp.51.6.745CrossRefPubMedPubMedCentral

22.

Grealish S, Diguet E, Kirkeby A et al (2014) Human ESC-derived dopamine neurons show similar Preclinical efficacy and potency to fetal neurons when grafted in a rat model of parkinson’s disease. Stem Cell 15:653–665. doi:10.1016/j.stem.2014.09.017

23.

Gross RE, Watts RL, Hauser RA et al (2011) Intrastriatal transplantation of microcarrier-bound human retinal pigment epithelial cells versus sham surgery in patients with advanced Parkinson’s disease: a double-blind, randomised, controlled trial. Lancet Neurol 10:509–519. doi:10.1016/S1474-4422[11]70097-7CrossRefPubMed

24.

Hagell P, Piccini P, Björklund A et al (2002) Dyskinesias following neural transplantation in Parkinson’s disease. Nat Neurosci 5:627–628. doi:10.1038/nn863PubMed

25.

Hermann A, Storch A, Liebau S (2013) Possible applications of new stem cell sources in neurology. Nervenarzt 84:943–948. doi:10.1007/s00115-013-3753-4CrossRefPubMed

26.

Höglinger GU, Rizk P, Muriel MP et al (2004) Dopamine depletion impairs precursor cell proliferation in Parkinson disease. Nat Neurosci 7:726–735. doi:10.1038/nn1265CrossRefPubMed

27.

Huisman E, Uylings HBM, Hoogland PV (2004) A 100 % increase of dopaminergic cells in the olfactory bulb may explain hyposmia in Parkinson’s disease. Mov Disord 19:687–692. doi:10.1002/mds.10713CrossRefPubMed

28.

Kordower JH, Chu Y, Hauser RA et al (2008) Lewy body-like pathology in long-term embryonic nigral transplants in Parkinson’s disease. Nat Med 14:504–506. doi:10.1038/nm1747CrossRefPubMed

29.

Kuhn HG, Dickinson-Anson H, Gage FH (1996) Neurogenesis in the dentate gyrus of the adult rat: age-related decrease of neuronal progenitor proliferation. J Neurosci 16:2027–2033PubMed

30.

Kuhn HG, Winkler J, Kempermann G et al (1997) Epidermal growth factor and fibroblast growth factor-2 have different effects on neural progenitors in the adult rat brain. J Neurosci 17:5820–5829PubMed

31.

Lanfer B, Hermann A, Kirsch M et al (2010) Directed growth of adult human white matter stem cell – derived neurons on aligned fibrillar collagen. Tissue Eng Part A 16:1103–1113. doi:10.1089/ten.TEA.2009.0282CrossRefPubMed

32.

Lazarini FO, Lledo P‑M (2011) Is adult neurogenesis essential for olfaction? Trends Neurosci 34:20–30. doi:10.1016/j.tins.2010.09.006CrossRefPubMed

33.

Lee S‑J, Desplats P, Sigurdson C et al (2010) Cell-to-cell transmission of non-prion protein aggregates. Nat Rev Neurol 6:702–706. doi:10.1038/nrneurol.2010.145CrossRefPubMed

34.

Li J‑Y, Englund E, Holton JL et al (2008) Lewy bodies in grafted neurons in subjects with Parkinson’s disease suggest host-to-graft disease propagation. Nat Med 14:501–503. doi:10.1038/nm1746CrossRefPubMed

35.

Li J‑Y, Englund E, Widner H et al (2010) Characterization of Lewy body pathology in 12-and 16-year-old intrastriatal mesencephalic grafts surviving in a patient with Parkinson’s disease. Mov Disord 25:1091–1096. doi:10.1002/mds.23012CrossRefPubMed

36.

Li W, Englund E, Widner H et al (2016) Extensive graft-derived dopaminergic innervation is maintained 24 years after transplantation in the degenerating parkinsonian brain. Proc Natl Acad Sci USA. doi:201605245. doi:10.1073/pnas.1605245113

37.

Lim Y, Kehm VM, Li C et al (2010) Forebrain overexpression of alpha-synuclein leads to early postnatal hippocampal neuron loss and synaptic disruption. Exp Neurol 221:86–97. doi:10.1016/j.expneurol.2009.10.005CrossRefPubMed

38.

Lindvall O, Backlund EO, Farde L et al (1987) Transplantation in Parkinson’s disease: Two cases of adrenal medullary grafts to the putamen. Ann Neurol 22:457–468. doi:10.1002/ana.410220403CrossRefPubMed

39.

Lindvall O, Sawle G, Widner H et al (1994) Evidence for long-term survival and function of dopaminergic grafts in progressive Parkinson’s disease. Ann Neurol 35:172–180. doi:10.1002/ana.410350208CrossRefPubMed

40.

Madrazo I, Drucker-Colín R, Díaz V et al (2010) Open microsurgical autograft of adrenal medulla to the right caudate nucleus in two patients with intractable parkinson’s disease. N Engl J Med 316:831–834. doi:10.1056/NEJM198704023161402CrossRef

41.

Marxreiter F, Ettle B, May VEL et al (2013) Neurobiology of disease. Neurobiol Dis 59:38–51. doi:10.1016/j.nbd.2013.07.004CrossRefPubMedPubMedCentral

42.

Marxreiter F, Nuber S, Kandasamy M et al (2009) Changes in adult olfactory bulb neurogenesis in mice expressing the A30P mutant form of alpha-synuclein. Eur J Neurosci 29:879–890. doi:10.1111/j.1460-9568.2009.06641.xCrossRefPubMed

43.

Masliah E, Rockenstein E, Mallory M et al (2000) Dopaminergic loss and inclusion body formation in alpha-synuclein mice: implications for neurodegenerative disorders. Science 287:1265–1269CrossRefPubMed

44.

Melrose HL, Lincoln SJ, Tyndall GM, Farrer MJ (2006) Parkinson’s disease: a rethink of rodent models. Exp Brain Res 173:196–204. doi:10.1007/s00221-006-0461-3CrossRefPubMed

45.

Messier B, Leblond CP, Smart I (1958) Presence of DNA synthesis and mitosis in the brain of young adult mice. Exp Cell Res 14:224–226CrossRefPubMed

46.

Morgane PJ, Galler JR, Mokler DJ (2005) A review of systems and networks of the limbic forebrain/limbic midbrain. Prog Neurobiol 75:143–160. doi:10.1016/j.pneurobio.2005.01.001CrossRefPubMed

47.

Muller J, Ossig C, Greiner JFW et al (2014) Intrastriatal transplantation of adult human neural crest-derived stem cells improves functional outcome in parkinsonian rats. Stem Cells Transl Med 4:31–43. doi:10.5966/sctm.2014-0078CrossRefPubMedPubMedCentral

48.

Negoias S, Croy I, Gerber J et al (2010) Reduced olfactory bulb volume and olfactory sensitivity in patients with acute major depression. Neuroscience 169:415–421. doi:10.1016/j.neuroscience.2010.05.012CrossRefPubMed

49.

Nuber S, Harmuth F, Kohl Z et al (2013) A progressive dopaminergic phenotype associated with neurotoxic conversion of α‑synuclein in BAC-transgenic rats. Brain 136:412–432. doi:10.1093/brain/aws358CrossRefPubMedPubMedCentral

50.

Nuber S, Petrasch-Parwez E, Winner B et al (2008) Neurodegeneration and motor dysfunction in a conditional model of Parkinson’s disease. J Neurosci 28:2471–2484. doi:10.1523/JNEUROSCI.3040-07.2008CrossRefPubMed

51.

Olanow CW, Goetz CG, Kordower JH et al (2003) A double-blind controlled trial of bilateral fetal nigral transplantation in Parkinson’s disease. Ann Neurol 54:403–414. doi:10.1002/ana.10720CrossRefPubMed

52.

Olanow CW, Stern MB, Sethi K (2009) The scientific and clinical basisi for the treatment of Parkinson’s disease. Neurology 72:1–S1. doi:10.1212/WNL.0b013e318198daceCrossRef

53.

Papez JW (1939) Connections of the pulivar. Arch Neurol Psychiatry 41:277. doi:10.1001/archneurpsyc.1939.02270140063005CrossRef

54.

Park J‑H, Enikolopov G (2010) Transient elevation of adult hippocampal neurogenesis after dopamine depletion. Exp Neurol 222:267–276. doi:10.1016/j.expneurol.2010.01.004CrossRefPubMedPubMedCentral

55.

Piccini P, Brooks DJ, Björklund A et al (1999) Dopamine release from nigral transplants visualized in vivo in a Parkinson’s patient. Nat Neurosci 2:1137–1140. doi:10.1038/16060CrossRefPubMed

56.

Pont-Sunyer C, Hotter A, Gaig C et al (2015) The Onset of Nonmotor Symptoms in Parkinson’s disease [The ONSET PD Study]. Mov Disord 30:229–237. doi:10.1002/mds.26077CrossRefPubMed

57.

Pont-Sunyer C, Hotter A, Gaig C et al (2015) The Onset of Nonmotor Symptoms in Parkinson’s disease [The ONSET PD Study]. Mov Disord 30:229–237. doi:10.1002/mds.26077CrossRefPubMed

58.

Redmond DE, Roth RH, Spencer DD et al (1993) Neural transplantation for neurodegenerative diseases: past, present, and future. Ann N Y Acad Sci 695:258–266CrossRefPubMed

59.

Rockenstein E, Mallory M (2002) Differential neuropathological alterations in transgenic mice expressing α‑synuclein from the platelet-derived growth factor and Thy-1 promoters. J Neurosci Res. doi:10.1002/jnr.10231

60.

Rotheneichner P, Lange S, O’Sullivan A et al (2014) Hippocampal neurogenesis and antidepressive therapy: shocking relations. Neural Plast 2014:1–14. doi:10.1155/2014/723915CrossRef

61.

Sanai N, Tramontin AD, Quiñones-Hinojosa A et al (2004) Unique astrocyte ribbon in adult human brain contains neural stem cells but lacks chain migration. Nature 427:740–744. doi:10.1038/nature02301CrossRefPubMed

62.

Sano K, Sato F, Hoshino T, Nagai M (1965) Experimental and clinical studies of radiosensitizers in brain tumors, with special reference to BUdR-antimetabolite continuous regional infusion-radiation therapy [BAR therapy. Neurol Med Chir (Tokyo) 7:51–72CrossRef

63.

Schober A (2004) Classic toxin-induced animal models of Parkinson’s disease: 6‑OHDA and MPTP. Cell Tissue Res 318:215–224. doi:10.1007/s00441-004-0938-yCrossRefPubMed

64.

Schurig K, Zieris A, Hermann A et al (2015) Neurotropic growth factors and glycosaminoglycan based matrices to induce dopaminergic tissue formation. Biomaterials 67:205–213. doi:10.1016/j.biomaterials.2015.07.029CrossRefPubMed

65.

Shiba M, Bower JH, Maraganore DM et al (2000) Anxiety disorders and depressive disorders preceding Parkinson’s disease: a case-control study. Mov Disord 15:669–677CrossRefPubMed

66.

Spalding KL, Bergmann O, Alkass K et al (2013) Dynamics of hippocampal neurogenesis in adult humans. Cell 153:1219–1227. doi:10.1016/j.cell.2013.05.002CrossRefPubMedPubMedCentral

67.

Spillantini MG, Schmidt ML, Lee VM et al (1997) Alpha-synuclein in Lewy bodies. Nature 388:839–840. doi:10.1038/42166CrossRefPubMed

68.

Stover NP, Bakay RAE, Subramanian T et al (2005) Intrastriatal implantation of human retinal pigment epithelial cells attached to microcarriers in advanced Parkinson disease. Arch Neurol 62:1833–1837. doi:10.1001/archneur.62.12.1833CrossRefPubMed

69.

Suzuki K, Okada K, Wakuda T et al (2010) Destruction of Dopaminergic neurons in the midbrain by 6‑Hydroxydopamine decreases Hippocampal cell proliferation in rats: reversal by Fluoxetine. PLoS ONE 5:e9260. doi:10.1371/journal.pone.0009260.g006CrossRefPubMedPubMedCentral

70.

van den Berge SA, van Strien ME, Korecka JA et al (2011) The proliferative capacity of the subventricular zone is maintained in the parkinsonian brain. Brain 134:3249–3263. doi:10.1093/brain/awr256CrossRefPubMed

71.

Winkler J, Kassubek J (2011) Parkinson’s disease risk score: moving to a premotor diagnosis. J Neurol 258:311–315. doi:10.1007/s00415-011-5952-xCrossRef

72.

Winner B, Couillard-Despres S, Geyer M et al (2008) Dopaminergic lesion enhances growth factor-induced striatal neuroblast migration. J Neuropathol Exp Neurol 67:105–116. doi:10.1097/nen.0b013e3181630cffCrossRefPubMed

73.

Winner B, Desplats P, Hagl C et al (2009) Dopamine receptor activation promotes adult neurogenesis in an acute Parkinson model. Exp Neurol 219:543–552. doi:10.1016/j.expneurol.2009.07.013CrossRefPubMed

74.

Winner B, Geyer M, Couillard-Despres S et al (2006) Striatal deafferentation increases dopaminergic neurogenesis in the adult olfactory bulb. Exp Neurol 197:113–121. doi:10.1016/j.expneurol.2005.08.028CrossRefPubMed

75.

Winner B, Jappelli R, Maji SK et al (2011) In vivo demonstration that alpha-synuclein oligomers are toxic. Proc Natl Acad Sci U S A 108:4194–4199. doi:10.1073/pnas.1100976108CrossRefPubMedPubMedCentral

76.

Winner B, Lie DC, Rockenstein E et al (2004) Human wild-type alpha-synuclein impairs neurogenesis. J Neuropathol Exp Neurol 63:1155–1166CrossRefPubMed

77.

Yamada M (2004) Neurogenesis in olfactory bulb identified by retroviral labeling in normal and 1‑methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated adult mice. Neuroscience 124:173–181. doi:10.1016/j.neuroscience.2003.10.040CrossRefPubMed

78.

Yang D, Li Q, Fang L et al (2011) Reduced neurogenesis and pre-synaptic dysfunction in the olfactory bulb of a rat model of depression. Neuroscience 192:609–618. doi:10.1016/j.neuroscience.2011.06.043CrossRefPubMed

Titel: Zellersatz und adulte Neurogenese beim idiopathischen Parkinson-Syndrom
verfasst von: F. Marxreiter
A. Storch
Prof. Dr. J. Winkler
Publikationsdatum: 07.07.2016
Verlag: Springer Berlin Heidelberg
Schlagwort: Parkinson-Krankheit
Erschienen in: Der Nervenarzt / Ausgabe 8/2016
Print ISSN: 0028-2804
Elektronische ISSN: 1433-0407
DOI: https://doi.org/10.1007/s00115-016-0157-2

Neu in den Fachgebieten Neurologie und Psychiatrie

25.04.2024 | Hypotonie | Nachrichten

Springer Medizin

Zellersatz und adulte Neurogenese beim idiopathischen Parkinson-Syndrom

Zusammenfassung

Neu in den Fachgebieten Neurologie und Psychiatrie

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

Frühe Alzheimertherapie lohnt sich

Viel Bewegung in der Parkinsonforschung

Demenzkranke durch Antipsychotika vielfach gefährdet

Springer Medizin

Zusammenfassung

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 8/2016

CME: Immunneuropathien

Koordinierte Schlaganfallnachsorge durch Case Management auf der Basis eines standardisierten Behandlungspfades

Nichtinvasive Stimulationsverfahren in der Neurologie

Spontanes Liquorunterdrucksyndrom und Marfan-Syndrom

Invasive Neurologie im Fokus

Stroke Summer School 2016 in Mühlheim

Neu in den Fachgebieten Neurologie und Psychiatrie

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

Frühe Alzheimertherapie lohnt sich

Viel Bewegung in der Parkinsonforschung

Demenzkranke durch Antipsychotika vielfach gefährdet